Genmab A/S (GNMSF) Cash from Financing Activities (2018 - 2026)

Genmab A (GNMSF) has 8 years of Cash from Financing Activities data on file, last reported at -$177.0 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 1261.54% year-over-year to -$177.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.0 billion (up 37.11% YoY) and the FY2025 annual result came in at $4.8 billion, up 946.11% from the prior year.
• Cash from Financing Activities climbed to -$177.0 million in Q1 2026, from -$440.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of -$13.0 million in Q1 2025 to a low of -$566.0 million in Q4 2024.
• A 4-year average of -$319.8 million and a median of -$419.0 million in 2025 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2025 — Cash from Financing Activities jumped 84.71% — and 2026, when it slumped 1261.54%.
• Tracing GNMSF's Cash from Financing Activities over 4 years: stood at -$89.0 million in 2023, then tumbled by 535.96% to -$566.0 million in 2024, then advanced by 22.26% to -$440.0 million in 2025, then surged by 59.77% to -$177.0 million in 2026.
• The last three Cash from Financing Activities figures came in at -$177.0 million (Q1 2026), -$440.0 million (Q3 2025), and -$419.0 million (Q2 2025), per Business Quant data.